For Research Use Only. Melanotan 2 (MT-II) is provided strictly for laboratory and scientific research purposes. It is not intended for human or veterinary use. All information presented here is derived from publicly available scientific literature and is intended solely to support in vitro, in vivo (non-human), or analytical research applications. Researchers must comply with all applicable UK regulations, including MHRA guidelines, institutional review boards, and local ethics requirements.
Abstract
Melanotan 2 (MT-II) is a synthetic cyclic heptapeptide analogue of α-melanocyte-stimulating hormone (α-MSH). It functions as a non-selective agonist at melanocortin receptors (MCRs) and has been utilized in various preclinical studies investigating melanocortin system pharmacology, receptor binding, and downstream signaling pathways.
Chemical and Structural Characteristics
Melanotan 2 is a cyclic lactam-bridged heptapeptide with the sequence Ac-Nle⁴-Asp⁵-His⁶-D-Phe⁷-Arg⁸-Trp⁹-Lys¹⁰-NH₂.
This structural modification enhances metabolic stability compared to the endogenous linear α-MSH peptide. It exhibits high affinity and agonist activity at multiple melanocortin receptor subtypes, particularly MC1R, MC3R, MC4R, and MC5R.
Source: ScienceDirect Overview
Mechanism of Action in Research Models
In laboratory settings, Melanotan 2 binds to and activates melanocortin receptors, which are G-protein-coupled receptors expressed in various tissues across model organisms. Activation of these receptors modulates intracellular signaling pathways, including cAMP production and other secondary messengers.
Receptor Selectivity Profile
Non-selective agonism across multiple MCR subtypes allows researchers to study cross-talk between pathways in controlled experimental systems.
Source: Wikipedia — Melanotan II (Research Context)
In Vitro Applications
Commonly used in cell culture models to investigate receptor pharmacology, ligand binding assays, and signal transduction.
In Vivo (Animal) Models
Employed in preclinical studies examining melanocortin system physiology in rodents and other laboratory animals.
Historical Development in Scientific Research
Melanotan 2 was originally synthesized at the University of Arizona in the 1980s–1990s during efforts to develop stable analogues of α-MSH for basic research into melanocortin biology.
Early preclinical work focused on its potency and duration of action relative to native peptides. Subsequent studies have utilized it as a pharmacological tool to probe melanocortin receptor function.
Source: University of Arizona Preformulation Studies
Research Applications and Considerations
Melanotan 2 continues to serve as a tool compound in:
- Melanocortin receptor binding and functional assays.
- Studies of peptide stability, pharmacokinetics in animal models, and formulation science.
- Broader investigations into the melanocortin system’s role in physiological regulation.
Laboratory Handling Notes
As with all research peptides, standard aseptic techniques, appropriate personal protective equipment, and proper waste disposal protocols should be followed. Stability and solubility data from preformulation studies can inform experimental design.
Researchers should source high-purity material from reputable suppliers and verify identity via HPLC, mass spectrometry, or other analytical methods.
Regulatory Status in the UK
Melanotan 2 is not approved for any non-research application. It is classified and sold exclusively for laboratory research use.
Use outside of approved scientific protocols may violate UK regulations. All researchers are responsible for ensuring full compliance with institutional, local, and national requirements.
Conclusion
Melanotan 2 represents an important synthetic tool in melanocortin peptide research due to its potency, stability, and receptor activity profile. Ongoing laboratory studies continue to utilize this compound to advance understanding of melanocortin receptor biology and peptide pharmacology.
This article is provided for educational purposes to support scientific research. For specific experimental protocols or data interpretation, consult primary peer-reviewed literature and qualified research professionals.
Selected References
- Dorr et al. (1996). Evaluation of melanotan-II… (PubMed)
- Hadley & Dorr (2006). Melanocortin peptide therapeutics…
- ScienceDirect and PubMed indexed reviews on melanocortin analogues.
